Price Alert

Recursion Pharmaceuticals... (RXRX)

NASDAQ: RXRX · Real-Time Price · USD

5.68

0.04 (0.71%)

At close: Aug 15, 2025, 11:13 AM

Recursion Pharmaceuticals Statistics

Share Statistics

Recursion Pharmaceuticals has 427.31M shares outstanding. The number of shares has increased by 42.35% in one year.

Shares Outstanding	427.31M
Shares Change (YoY)	42.35%
Shares Change (QoQ)	1.16%
Owned by Institutions (%)	71.66%
Shares Floating	332.14M
Failed to Deliver (FTD) Shares	374,160
FTD / Avg. Volume	1.33%

Short Selling Information

The latest short interest is 115.53M, so 26.65% of the outstanding shares have been sold short.

Short Interest	115.53M
Short % of Shares Out	26.65%
Short % of Float	28.6%
Short Ratio (days to cover)	3.77

Valuation Ratios

The PE ratio is -4 and the forward PE ratio is -4.5. Recursion Pharmaceuticals's PEG ratio is -0.57.

PE Ratio	-4
Forward PE	-4.5
PS Ratio	31.5
Forward PS	22.7
PB Ratio	1.79
P/FCF Ratio	-4.97
PEG Ratio	-0.57

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Recursion Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.1.

Current Ratio	3.81
Quick Ratio	3.81
Debt / Equity	0.1
Debt / EBITDA	-0.25
Debt / FCF	-0.29
Interest Coverage	-304.71

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$73.55K
Profits Per Employee	$-579.58K
Employee Count	800
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	-1.13M
Effective Tax Rate	0.24%

Stock Price Statistics

The stock price has increased by -12.27% in the last 52 weeks. The beta is 0.92, so Recursion Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.92
52-Week Price Change	-12.27%
50-Day Moving Average	5.37
200-Day Moving Average	6.21
Relative Strength Index (RSI)	43.96
Average Volume (20 Days)	28,079,556

Income Statement

In the last 12 months, Recursion Pharmaceuticals had revenue of 58.84M and earned -463.66M in profits. Earnings per share was -1.69.

Revenue	58.84M
Gross Profit	13.6M
Operating Income	-479M
Net Income	-463.66M
EBITDA	-426.72M
EBIT	-463.22M
Earnings Per Share (EPS)	-1.69

Full Income Statement

Balance Sheet

The company has 594.35M in cash and 108.49M in debt, giving a net cash position of 485.86M.

Cash & Cash Equivalents	594.35M
Total Debt	108.49M
Net Cash	485.86M
Retained Earnings	-1.43B
Total Assets	1.3B
Working Capital	423.13M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -359.17M and capital expenditures -13.7M, giving a free cash flow of -372.87M.

Operating Cash Flow	-359.17M
Capital Expenditures	-13.7M
Free Cash Flow	-372.87M
FCF Per Share	-1.36

Full Cash Flow Statement

Margins

Gross margin is 23.12%, with operating and profit margins of -814.09% and -788.02%.

Gross Margin	23.12%
Operating Margin	-814.09%
Pretax Margin	-789.93%
Profit Margin	-788.02%
EBITDA Margin	-725.24%
EBIT Margin	-814.09%
FCF Margin	-633.71%

Dividends & Yields

RXRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RXRX is $6, which is 13.4% higher than the current price. The consensus rating is "Hold".

Price Target	$6
Price Target Difference	13.4%
Analyst Consensus	Hold
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.45
Piotroski F-Score	2